Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
R&D113 LAI
- Development stage
- Unknown
- Lead developer
- Bostal Pharma
- Modality
- Small Molecules
- Administration
- Intramuscular
01
Overview
R&D113 LAI is a long-acting injectable (LAI) formulation of paliperidone palmitate being developed by Bostal Drug Delivery for the treatment of schizophrenia and bipolar I disorder. The program utilizes proprietary delivery technology to achieve extended-release profiles, with development focusing on 3-month, 6-month, and 8-month dosing intervals. Paliperidone, the active metabolite of risperidone, is an atypical antipsychotic that acts as an antagonist at dopamine D2 and serotonin 5-HT2A receptors, as well as alpha-adrenergic and H1 histaminergic receptors. By significantly reducing the frequency of administration, R&D113 LAI aims to improve patient adherence and long-term outcomes in psychiatric care, with the 8-month formulation representing a potential best-in-class dosing duration.
Beyond the preview
Go deeper on R&D113 LAI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on R&D113 LAI.